Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votesGovInfo API
Floor speeches, reports, bill textFederal Election Commission (FEC)
Campaign financeVoteView (UCLA)
Ideology scores (DW-NOMINATE)GovTrack.us
Misconduct data (CC0)U.S. Census Bureau
District demographics
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

HR7050Referred to Committee

Homeopathic Drug Product Safety, Quality, and Transparency Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-01-14
Introduced
4
Cosponsors
HR
ⓘ
Type

Sponsor

Pete Sessions
Pete Sessions
Republican · TX · Representative
Votes with party: 98.7% (552 recorded votes)

Full profile: /officials/S000250

Source: Congress.gov · FEC

Cosponsors (4)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Jonathan L. Jackson (D-IL-1)Original· 2026-01-14
  • Mike Kennedy (R-UT-3)Original· 2026-01-14
  • Burgess Owens (R-UT-4)· 2026-04-21

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the House Committee on Energy and Commerce.

2026-01-14

Source: Congress.gov

Committee Activity

Currently in

  • House Committee on Energy and CommerceReferred To · 2026-01-14

Previously

  • Energy and Commerce CommitteeReferred To · 2026-01-14

Plain-English Summary

The legislation would require homeopathic products sold in the United States to meet stricter safety and quality standards, similar to those for conventional drugs, and would mandate that manufacturers clearly disclose their ingredients and manufacturing processes on product labels. This would affect homeopathic remedy makers and sellers, as well as consumers who use these products, by ensuring greater transparency about what they're buying and how it was made. The bill aims to give the FDA more authority to oversee the homeopathic industry, which currently operates under looser regulations than pharmaceutical drugs.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • HR8312Fraud Prevention and Accountability Act
    Referred to Committee · 2026-04-29
  • HR8290Exchange Rate Accountability Act of 2026
    Reported by Committee · 2026-04-21
  • HR3420Words Matter Act of 2025
    Referred to Committee · 2026-03-26
  • HR7953FAIR ACT
    Referred to Committee · 2026-03-17